Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | CDC25B | P30305 | 3/20 | 0.52 |
| ▸ | CDC25A | P30304 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27398601 | 0.85 | MEN1 (0.62) | MAPK1SMN1; SMN2HTTCYP1A2MEN1 | |
| SCHEMBL27386759 | 0.85 | CYP1A2 (0.53) | MAPK1SMN1; SMN2ALOX15HTTCYP1A2 | |
| SCHEMBL27389198 | 0.84 | HSD17B10 (0.66) | MAPK1SMN1; SMN2CYP1A2POLBMEN1 | |
| SCHEMBL20945035 | 0.82 | CYP1A2 (0.70) | MAPK1HTTCYP1A2POLBCDC25B | |
| SCHEMBL5821136 | 0.79 | CYP1A2 (0.65) | MAPK1SMN1; SMN2HTTCYP1A2POLB | |
| SCHEMBL27570670 | 0.78 | PLA2G1B (0.65) | MAPK1SMN1; SMN2ALOX15HTTPOLB | |
| SCHEMBL9657352 | 0.76 | CYP1A2 (0.71) | MAPK1HTTCYP1A2POLBMEN1 | |
| SCHEMBL3259551 | 0.75 | CYP1A2 (1.00) | HTTCYP1A2MEN1KMT2AL3MBTL1 | |
| SCHEMBL25430151 | 0.75 | POLB (0.64) | MAPK1SMN1; SMN2ALOX15HTTPOLB | |
| SCHEMBL31542122 | 0.75 | POLB (0.64) | MAPK1SMN1; SMN2ALOX15HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415345-B | Pyridazinone-based broad-spectrum anti-influenza inhibitors | 豪夫迈·罗氏有限公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3478671-B1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-05-13 | — | — | EP | disclosed |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| CN-1067052-A | The diaminophthalimides and the analogue thereof that replace | CIBA GEIGY AG (CH) | 1992-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | ABCG2, PIR, PRNP | MAPK1 1411/4885SMN1; SMN2 4559/4885ALOX15 3534/4885 |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | ABCG2, PIR, PRNP | MAPK1 1411/4885SMN1; SMN2 4559/4885ALOX15 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.